en · de · es · fr · pt
field-notes.peptides4800.com › Data › Molecular Background And Immune Action — Deep Dive

Molecular Background And Immune Action — Deep Dive

By Editorial Desk · published 2026-03-21 · last reviewed 2026-04-07 · Data

thymalfasin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.

Molecular Background and Immune Action

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Identity and Molecular Background

The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.

Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.

Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular mass≈3,108 DaSynthetic 28-residue peptide
Amino acid count28N-terminal serine carries an acetyl group
AppearanceWhite to off-white powderLyophilized solid
Water solubilityFreely solubleDissolves in aqueous buffer
Common synonymsThymalfasin; Tα1Thymalfasin is the international nonproprietary name

Further detail

Lipolysis, the removal of the fatty acid chains from the glycerol to which they are bound in their storage form as triglycerides (or fats), is carried out by lipases. These lipases are activated by high epinephrine and glucagon levels in the blood (or norepinephrine secreted by sympathetic nerves in adipose tissue), caused by declining blood glucose levels after meals, which simultaneously lowers the insulin level in the blood. Once freed from glycerol, the free fatty acids enter the blood, which transports them, attached to plasma albumin, throughout the body. Long-chain free fatty acids enter metabolizing cells (i.e. most living cells in the body except red blood cells and neurons in the central nervous system) through specific transport proteins, such as the SLC27 family fatty acid transport protein. Red blood cells do not contain mitochondria and are therefore incapable of metabolizing fatty acids; the tissues of the central nervous system cannot use fatty acids, despite containing mitochondria, because long-chain fatty acids (as opposed to medium-chain fatty acids) cannot cross the blood-brain barrier into the interstitial fluids that bathe these cells. Once inside the cell, long-chain-fatty-acid—CoA ligase catalyzes the reaction between a fatty acid molecule with ATP (which is broken down to AMP and inorganic pyrophosphate) to give a fatty acyl-adenylate, which then reacts with free coenzyme A to give a fatty acyl-CoA molecule.

=== Sport === Paul Frère (1917–2008), Belgian racing driver Wilfried Nancy (born 1977), football manager Jérôme Le Banner (born 1972), kickboxer and K-1 fighter Vikash Dhorasoo, (born 1973), international footballer Olivier Davidas (born 1981), footballer Dimitri Dragin (born 1984), judoka Julien Faubert (born 1983), footballer Kevin Anin (born 1986), footballer Gueïda Fofana (born 1991), footballer Jaylen Hoard (born 1999), French-American basketball player for Hapoel Tel Aviv Dan Delaunay (born 1995), professional footballer.

== Limitations == Despite its aforementioned advantages as a specialized tool, the B1H system does have some drawbacks. First, the B1H selection system is limited in its capacity to determine the binding specificities of transcription factors with lengthy binding sites. This arises from the fact that the number of randomized “prey” clones required to represent all possible target sequences increases exponentially with the number of nucleotides in that target sequence. Second, some eukaryotic factors may not express or fold efficiently in the bacterial system, attributed to differing regulatory networks and transcriptional machinery. Hence when working with DNA-binding proteins of eukaryotic origin, a yeast-based hybrid system may be beneficial. Third, the B1H system may not be ideally suited for transcription factors that recognize binding sites with low affinity. The logic here is that competition created by binding sites elsewhere in the bacterial genome may limit the signal that can be realized from a single binding site that is present upstream of the reporter.

The dawn phenomenon, sometimes called the dawn effect, is an observed increase in blood sugar (glucose) levels that takes place in the early-morning, often between 2 a.m. and 8 a.m. First described by Schmidt in 1981 as an increase of blood glucose or insulin demand occurring at dawn, this naturally occurring phenomenon is frequently seen among the general population and is clinically relevant for patients with diabetes as it can affect their medical management. In contrast to Chronic Somogyi rebound, the dawn phenomenon is not associated with nocturnal hypoglycemia.

In Japan, public universities are run by local governments, either prefectural or municipal. According to the Ministry of Education, public universities have "provided an opportunity for higher education in a region and served the central role of intellectual and cultural base for the local community in the region" and are "expected to contribute to social, economical and cultural development in the region". This contrasts with the research-oriented aspects of national universities. In 2010, 127,872 students were attending 95 public universities, compared to 86 national universities and 597 private universities in Japan. Many public universities are relatively new; in 1980, there were only 34 public universities in Japan. Since July 2003, public universities may incorporate under the Local Independent Administrative Institutions Law.

Sources: en.wikipedia.org

Related pages on this site

Supporting material

== Applications == Peroxidase can be used for treatment of industrial waste waters. For example, phenols, which are important pollutants, can be removed by enzyme-catalyzed polymerization using horseradish peroxidase. Thus phenols are oxidized to phenoxy radicals, which participate in reactions where polymers and oligomers are produced that are less toxic than phenols. It also can be used to convert toxic materials into less harmful substances. There are many investigations about the use of peroxidase in many manufacturing processes like adhesives, computer chips, car parts, and linings of drums and cans. Other studies have shown that peroxidases may be used successfully to polymerize anilines and phenols in organic solvent matrices. Peroxidases are sometimes used as histological markers. Cytochrome c peroxidase is used as a soluble, easily purified model for cytochrome c oxidase.

Cyanogen bromide is the inorganic compound with the formula BrCN. It is a colorless solid that is widely used to modify biopolymers, fragment proteins and peptides (cuts the C-terminus of methionine), and synthesize other compounds. The compound is classified as a pseudohalogen.

Slavery is the ownership of a person as property, especially in regard to their labour. It is an economic phenomenon and its history resides in economic history. Slavery typically involves compulsory work, with the slave's location of work and residence dictated by the party that holds them in bondage. Enslavement is the placement of a person into slavery, and the person is called a slave or an enslaved person. Many historical cases of enslavement occurred as a result of breaking the law, becoming indebted, suffering a military defeat, or exploitation for cheaper labor; other forms of slavery were instituted along demographic lines such as race or sex. Slaves would be kept in bondage for life, or for a fixed period of time after which they would be granted freedom. Although slavery is usually involuntary and involves coercion, there are also cases where people voluntarily enter into slavery to pay a debt or earn money due to poverty. In the course of human history, slavery was a common feature of civilization, and existed in most societies throughout history, but it is now outlawed in every country in the world except as a punishment for a crime. In general there were two types of slavery throughout human history: domestic and productive. In chattel slavery, the slave is legally rendered the personal property (chattel) of the slave owner. In economics, the term de facto slavery describes the conditions of unfree labour and forced labour that most slaves endure.

==== Croatian ==== Croatian Catholic Union of the United States of America and Canada - Founded in 1921. Headquarters in Hobart, Indiana. Convention meets quadrennially. In 1978 membership was described as being open to Croats and their spouses who are Latin or Greek rite Catholics. In 1997 it was described as open to all Latin or Greek rite Catholics in the United States and Canada. In 1965 the union had 13,772. In 1978 the Union had 119 local units in 16 states and Canada with about 13,500 in 1978. In 1988 it was reported to have 13,000. The union assists the Catholic church, theology students, scholarships, and disaster relief. In addition, the union performs "works of mercy" extended to members who are ill or hospitalized, and arranges sporting events. Merged with the Croatian Fraternal Union in 2006. Croatian Fraternal Union

Sources: en.wikipedia.org

Notes from published material

Purification of the crude synthesis solution increases usability of the products by improving the chances of successfully obtaining full-length oligo sequences. Successfully synthesized long oligo-sequences are scarce; the solution predominantly contains truncated or failed oligo-sequences. By tagging only full-length oligonucleotides with polymerizable tagging phosphoramidite (PTP) and incorporating them into polyacrylamide gel, truncated, or untagged, sequences are washed away, and the desired sequences are retained. This purification method is coined catching-by-polymerization (CBP) and allows for successful recovery of synthesized sequences. Utilizing these methods, successful direct chemical synthesis of ultra-long (800-mer and 1728-mer) oligonucleotides has been achieved.

==== Co-evolutionary evidence ==== An independent molecular analysis trying to establish the dates when bat ectoparasites (bedbugs) evolved came to the conclusion that bedbugs similar to those known today (all major extant lineages, all of which feed primarily on bats) had already diversified and become established over 100 million years ago, suggesting that they initially all evolved on non-bat hosts and "bats were colonized several times independently, unless the evolutionary origin of bats has been grossly underestimated". No analysis has provided estimates for the age of the flea lineages associated with bats. The oldest known members of a different lineage of bat ectoparasites (bat flies), however, are from roughly 20 million years ago, well after the origin of bats. The bat-ectoparasitic earwig family Arixeniidae has no fossil record but is not believed to originate more than 23 million years ago.

== Clinical significance == Mutations in the type VI collagen genes are associated with Bethlem myopathy and Ullrich congenital muscular dystrophy (UCMD). Typically, both Bethlem myopathy and autosomal recessive UCMD patients are heterozygous for mutations in the three type VI collagen alpha chains, but only the former exhibit symptoms. Of the three alpha chains, COL6A3 mutations contribute to only 18% of the Bethlem myopathy and UCMD cases. A study on UCMD mutations by Zhang et al found only one non-pathogenic mutation in COL6A3. Nonetheless, knockdown of mutant COL6A3 in patient fibroblast cells using siRNA has successfully improved cellular deposition of type VI collagen in autosomal dominant UCMD, and may become a promising treatment for it. Though high expression levels of COL6A3 have been correlated with obesity and diabetes in mice, this relationship was not observed in humans. Other disorders involving muscle and connective tissue include weakness, joint laxity and contractures, and abnormal skin.

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha 1 made of?

It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.

Is thymosin alpha 1 a hormone?

It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.

Where is thymosin alpha 1 approved?

Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.

What is thymosin alpha 1?

It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.

Network